MA56226B1 - Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale - Google Patents

Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale

Info

Publication number
MA56226B1
MA56226B1 MA56226A MA56226A MA56226B1 MA 56226 B1 MA56226 B1 MA 56226B1 MA 56226 A MA56226 A MA 56226A MA 56226 A MA56226 A MA 56226A MA 56226 B1 MA56226 B1 MA 56226B1
Authority
MA
Morocco
Prior art keywords
treatment
adrenal hyperplasia
congenital adrenal
pharmaceutical formulations
solid forms
Prior art date
Application number
MA56226A
Other languages
English (en)
Other versions
MA56226A (fr
Inventor
Robert H. FARBER
Gordon Raphael LOEWEN
Xiaoping Zhang
Nagdeep GIRI
Jean L. CHAN
Scott Stirn
Brian Sayers
Graeme Taylor
Christina Marie COSTA
Stacy PARKS
Anthony D. VICKERY
Kristie M. DOWNING
Kingsley Iyoha
Ayanda NGWENYA-JONES
Anne Charlier
Gurvinder Singh MEHTON
Original Assignee
Sanofi
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi, Neurocrine Biosciences, Inc. filed Critical Sanofi
Publication of MA56226A publication Critical patent/MA56226A/fr
Publication of MA56226B1 publication Critical patent/MA56226B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/52—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of imines or imino-ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/02—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of compounds containing imino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des méthodes liées au traitement de l'hyperplasie congénitale des surrénales chez un sujet en ayant besoin, comprenant l'administration de 4-(2-chloro-4-méthoxy-5-méthylphényl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-méthylphényl)éthyl]-5-méthyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Formule I), ou d'un sel pharmaceutiquement acceptable de celle-ci. L'invention concerne également des formulations pharmaceutiques et des formes solides de 4-(2-chloro-4-méthoxy-5-méthylphényl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-méthylphényl)éthyl]-5-méthyl-N-prop-2-ynyl-1,3-thiazol-2-amine, ou un sel pharmaceutiquement acceptable de celle-ci, et leur utilisation dans le traitement de l'hyperplasie congénitale des surrénales (HCS).
MA56226A 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale MA56226B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776763P 2018-12-07 2018-12-07
US201962816674P 2019-03-11 2019-03-11
EP21213854.9A EP3984523B1 (fr) 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale

Publications (2)

Publication Number Publication Date
MA56226A MA56226A (fr) 2022-04-20
MA56226B1 true MA56226B1 (fr) 2025-11-28

Family

ID=69500780

Family Applications (2)

Application Number Title Priority Date Filing Date
MA56226A MA56226B1 (fr) 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MA054395A MA54395A (fr) 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054395A MA54395A (fr) 2018-12-07 2019-12-06 Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale

Country Status (27)

Country Link
US (4) US20220023266A1 (fr)
EP (4) EP3890706A2 (fr)
JP (7) JP7238130B2 (fr)
KR (3) KR20260085349A (fr)
CN (7) CN121129756A (fr)
AU (4) AU2019393256B2 (fr)
BR (1) BR112021010847A2 (fr)
CA (3) CA3121920A1 (fr)
DK (1) DK3984523T3 (fr)
ES (1) ES3052613T3 (fr)
FI (1) FI3984523T3 (fr)
HR (1) HRP20251224T1 (fr)
IL (3) IL283712B1 (fr)
LT (1) LT3984523T (fr)
MA (2) MA56226B1 (fr)
MD (1) MD3984523T2 (fr)
MX (3) MX2021006552A (fr)
PH (1) PH12021551290A1 (fr)
PL (1) PL3984523T3 (fr)
PT (1) PT3984523T (fr)
RS (1) RS67433B1 (fr)
SA (1) SA521421973B1 (fr)
SG (1) SG11202105930QA (fr)
SI (1) SI3984523T1 (fr)
SM (1) SMT202500435T1 (fr)
TW (4) TWI874339B (fr)
WO (3) WO2020115555A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 ｃｒｆ1 수용체 길항제
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) * 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CA3181084A1 (fr) * 2020-06-10 2021-12-16 Robert H. FARBER Antagoniste du recepteur crf1 pour le traitement de l'hyperplasie surrenale congenitale
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
WO2023049689A1 (fr) * 2021-09-21 2023-03-30 Reveragen Biopharma, Inc. Traitement de l'hypoplasie surrénale congénitale
WO2023163945A1 (fr) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
CN114715871B (zh) * 2022-04-26 2023-09-12 四川朗晟新材料科技有限公司 一种锂电池用改性磷酸铁锂正极材料及制备方法
EP4522129A1 (fr) * 2022-05-11 2025-03-19 Eli Lilly And Co. Compositions pharmaceutiques à base de glp1
KR20260005992A (ko) 2023-05-08 2026-01-12 뉴로크린 바이오사이언시즈 인코퍼레이티드 소아 대상체에서의 선천성 부신 과다형성증 치료를 위한 크리네서폰트의 투여 요법
WO2026072679A1 (fr) * 2024-09-25 2026-04-02 Manistee Therapeutics Inc. Procédés et compositions pour l'administration d'analogues de prostaglandine f2a

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (fr) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
AU4270297A (en) 1996-09-16 1998-04-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) * 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DK0977737T3 (da) 1997-04-22 2004-01-26 Janssen Pharmaceutica Nv CRF-antagonistisk quino- og quinazoline
WO1999010350A1 (fr) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company IMIDAZO[4,5c]PYRAZOLES A SUBSTITUTION AZOTE, EN TANT QU'ANTAGONISTES DE L'HORMONE DE LIBERATION DE LA CORTICOTROPINE
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
CA2369553A1 (fr) 1999-04-02 2000-10-12 Raymond F. Horvath N-benzimidazolylmethyl- et n-indolylmethyl-benzamides et leur application comme modulateurs de corticoliberine
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
JP3830727B2 (ja) * 2000-05-11 2006-10-11 セントラル硝子株式会社 光学活性α−メチル−ビス−３，５−（トリフルオロメチル）ベンジルアミンの製造方法
US7276526B2 (en) 2001-07-13 2007-10-02 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
CA2556160A1 (fr) 2004-02-13 2005-09-01 Pfizer Products Inc. Combinaisons therapeutiques d'antipsychotiques atypiques et d'antagonistes du facteur de liberation de la corticotrophine
US20060078623A1 (en) 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7652035B2 (en) 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
CN101142217B (zh) 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
JPWO2006126718A1 (ja) 2005-05-27 2008-12-25 田辺三菱製薬株式会社 ピラゾロピリミジン誘導体
CA2627923C (fr) 2005-11-10 2016-01-12 Topotarget Uk Limited Inhibiteurs d'histone desacetylase (hdac) pour le traitement du cancer
EP1961745A1 (fr) 2005-12-12 2008-08-27 Ono Pharmaceutical Co., Ltd. Compose heterocyclique bicyclique
WO2007069671A1 (fr) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. Compose heterocyclique bicyclique
PL1982178T3 (pl) * 2006-02-07 2014-02-28 Phenoquest Ag Sposoby leczenia zaburzeń afektywnych
EP1991547A2 (fr) 2006-03-09 2008-11-19 Pharmacopeia, Inc. Inhibiteurs de la 8-hétéroarylpurine mnk2 pour le traitement de troubles métaboliques
EP1834641A1 (fr) * 2006-03-16 2007-09-19 Sanofi-Aventis Antagonistes du CRF1 pour la préparation de médicaments pour le traitement du syndrome métabolique et/ou de l'obesité et/ou de la dyslipoproteinemie
EP2029136A4 (fr) 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc Traitement pour troubles dépressifs
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
JP2010507664A (ja) 2006-10-25 2010-03-11 武田薬品工業株式会社 ベンズイミダゾール化合物
WO2008082003A1 (fr) 2006-12-29 2008-07-10 Takeda Pharmaceutical Company Limited Composes heterocycliques lies par fusion developpant une activite antagoniste au crf
WO2008083070A1 (fr) 2006-12-29 2008-07-10 Neurogen Corporation Ligands des récepteurs du crf1 comprenant des groupes fonctionnels hétéroaryle bicycliques
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (fr) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. Dérivés de 8-aryl-4-alkylpyrrolo[2,3,4-dé]quinoléine-5(4h)-one et de 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-dé]quinoléine-5-ol
CN101381314A (zh) * 2007-09-05 2009-03-11 成都和康药业有限责任公司 (r)-(+)-n-炔丙基-1-茚胺的一种新的制备方法
WO2009042166A1 (fr) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Formes de dosage de bevirimat liquide pour une administration orale
WO2009144632A1 (fr) 2008-05-30 2009-12-03 Pfizer Limited Nouveaux composés
WO2010014687A1 (fr) 2008-07-31 2010-02-04 Bristol-Myers Squibb Company Dérivés de carbamate substitués en tant que modulateurs de l'activité du récepteur de facteur de libération de corticotropine
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010062718A1 (fr) 2008-11-03 2010-06-03 Synthes Usa, Llc Ensemble tige réglable
US8551996B2 (en) 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) * 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
JPWO2011043387A1 (ja) 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (fr) 2010-02-02 2014-10-15 Novartis AG Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
DE102010015143A1 (de) 2010-04-16 2011-10-20 Cts Chemical Industries Ltd. Stabile flüssige ölige gebrauchsfertige Formulierungen, Herstellung davon und Verwendung davon
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EP2836216B1 (fr) 2012-04-13 2022-06-08 Epizyme, Inc. Polythérapie anticancéreuse
US20150278438A1 (en) 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
JP2015516979A (ja) 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
MX377877B (es) 2013-01-14 2025-03-11 Infirst Healthcare Ltd Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
HK1220872A1 (zh) 2013-03-15 2017-05-19 Virun, Inc. 维生素e水溶性衍生物制剂及包含其的组合物
KR20210064407A (ko) 2014-01-21 2021-06-02 뉴로크린 바이오사이언시즈 인코퍼레이티드 선천성 부신 과형성 치료를 위한 ｃｒｆ1 수용체 길항제
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2015159170A2 (fr) * 2014-04-18 2015-10-22 Suven Life Sciences Limited Procédé amélioré pour la synthèse de 1-(4-méthoxyphényl) éthylamine et ses isomères
WO2016065177A1 (fr) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Procede de traitement de la depression et d'autres troubles lies au stress
KR102586138B1 (ko) 2015-02-06 2023-10-05 뉴로크린 바이오사이언시즈 인코퍼레이티드 [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
US20180355430A1 (en) 2015-04-02 2018-12-13 Hmnc Value Gmbh Genetic Predictors of a Response to Treatment with CRHR1 Antagonists
AU2016240213B2 (en) * 2015-04-02 2022-01-27 HMNC Holding GmbH Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists
WO2017031325A1 (fr) * 2015-08-18 2017-02-23 Forum Pharmaceuticals Inc. Composés d'oxadiazine et leurs procédés d'utilisation
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
CA3063938A1 (fr) 2017-05-17 2018-11-22 Denali Therapeutics Inc. Composes, compositions et methodes
WO2018219804A1 (fr) * 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Systèmes d'administration de médicaments auto-émulsifiants
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
US20200255436A1 (en) 2019-02-12 2020-08-13 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
KR20220052927A (ko) 2019-07-19 2022-04-28 스프루스 바이오사이언시스 인코포레이티드 선천성 부신 증식증의 치료 방법
US12383536B2 (en) 2019-09-27 2025-08-12 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods of use
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
CA3181084A1 (fr) * 2020-06-10 2021-12-16 Robert H. FARBER Antagoniste du recepteur crf1 pour le traitement de l'hyperplasie surrenale congenitale
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
US20240024330A1 (en) 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GB202100526D0 (en) 2021-01-15 2021-03-03 Redx Pharma Plc Pharmaceutical formulation
EP4301342A1 (fr) 2021-03-04 2024-01-10 Evonik Operations GmbH Snedds solides à base d'un mélange spécifique de polymères acryliques

Also Published As

Publication number Publication date
CN113518616B (zh) 2025-10-14
SA521421973B1 (ar) 2024-05-12
WO2020115555A3 (fr) 2020-08-06
AU2021289538A8 (en) 2023-06-15
ES3052613T3 (en) 2026-01-12
WO2020115555A2 (fr) 2020-06-11
AU2026204170A1 (en) 2026-06-18
US20230286932A1 (en) 2023-09-14
US20230233534A1 (en) 2023-07-27
CA3181126A1 (fr) 2021-12-16
IL298927A (en) 2023-02-01
SG11202105930QA (en) 2021-07-29
FI3984523T3 (fi) 2025-10-21
CN115087647A (zh) 2022-09-20
JP7238130B2 (ja) 2023-03-13
HRP20251224T1 (hr) 2025-12-19
JP2025157396A (ja) 2025-10-15
WO2021250468A2 (fr) 2021-12-16
JP2022508317A (ja) 2022-01-19
CN120817912A (zh) 2025-10-21
TWI916760B (zh) 2026-03-01
IL330232A (en) 2026-08-01
AU2025205083A1 (en) 2025-07-24
WO2021250468A8 (fr) 2022-08-04
RS67433B1 (sr) 2025-12-31
US20220023266A1 (en) 2022-01-27
KR20230038185A (ko) 2023-03-17
TW202547832A (zh) 2025-12-16
US12128033B2 (en) 2024-10-29
SMT202500435T1 (it) 2026-01-12
EP4164604A2 (fr) 2023-04-19
WO2021250468A3 (fr) 2022-01-20
JP2026042855A (ja) 2026-03-11
CA3160738A1 (fr) 2021-06-10
JP2023505232A (ja) 2023-02-08
IL283712A (en) 2021-07-29
JP7675717B6 (ja) 2025-06-23
US12582634B2 (en) 2026-03-24
SI3984523T1 (sl) 2026-01-30
TWI874339B (zh) 2025-03-01
MX2021006552A (es) 2021-07-07
CN121129756A (zh) 2025-12-16
WO2021111179A8 (fr) 2022-07-14
MA56226A (fr) 2022-04-20
JP7675717B2 (ja) 2025-05-13
IL283712B1 (en) 2026-08-01
EP3890706A2 (fr) 2021-10-13
KR20260085349A (ko) 2026-06-09
PL3984523T3 (pl) 2026-02-02
EP4069682A1 (fr) 2022-10-12
WO2021111179A1 (fr) 2021-06-10
MX2024001849A (es) 2024-02-29
AU2021289538A1 (en) 2023-02-09
LT3984523T (lt) 2025-12-10
PH12021551290A1 (en) 2022-03-28
CA3121920A1 (fr) 2020-06-11
KR20210100669A (ko) 2021-08-17
TW202033193A (zh) 2020-09-16
EP3984523B1 (fr) 2025-09-03
MD3984523T2 (ro) 2026-02-28
EP3984523A1 (fr) 2022-04-20
CN113518616A (zh) 2021-10-19
JP2023105239A (ja) 2023-07-28
DK3984523T3 (da) 2025-09-29
CN120284862A (zh) 2025-07-11
CN116322668A (zh) 2023-06-23
TWI895302B (zh) 2025-09-01
BR112021010847A2 (pt) 2021-09-08
TW202446384A (zh) 2024-12-01
CN120829398A (zh) 2025-10-24
US20240238257A1 (en) 2024-07-18
TW202136225A (zh) 2021-10-01
PT3984523T (pt) 2025-10-28
MA54395A (fr) 2022-03-16
AU2019393256A1 (en) 2021-07-29
AU2019393256B2 (en) 2025-07-31
JP2025036615A (ja) 2025-03-14
MX2022015551A (es) 2023-02-27
JP2023530084A (ja) 2023-07-13

Similar Documents

Publication Publication Date Title
SA521421973B1 (ar) عامل مضاد لمستقبل crf1، ومستحضرات صيدلانية وأشكال صلبة منها لعلاج فرط التنسج الكظري الخلقي
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
RU2470642C2 (ru) Аналоги птерина для лечения состояния, чувствительного к вн4
MA44935A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MA53927B1 (fr) Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel
MA38576B2 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA39972B1 (fr) Composés et compositions d'induction de la chondrogenèse
MA41139B1 (fr) Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
MA46342B1 (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA41985B1 (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
EP3443984A4 (fr) Composition pharmaceutique pour diminuer les symptômes et la maladie de l'infection respiratoire causée par le métapneumovirus humain (hmpv) qui comprend au moins un agent neutralisant la fonction des molécules tspl et/ou tslpr, et/ou ox40l et/ou cd177, et un excipient pharmaceutiquement acceptable, et leur utilisation
MA55726A (fr) Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation
EP3957326A4 (fr) Utilisation d'anticorps anti-pd-1 dans la préparation d'un médicament pour le traitement de tumeurs solides
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EP4138841A4 (fr) Formulation pour le traitement d'affections ophtalmiques
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
MA34297B1 (fr) Association d'inhibiteurs de la xanthine oxydase et d'antagonistes du récepteur de l'angiotensine ii et son utilisation